Immunoassay Market Size, Share, Trend Forecast by 2023
According to the new market research report "Immunoassay
Market by Product & Service
(Reagents & Kits, Analyzers, Software), Technology (ELISA, Rapid Test),
Platform (Radioimmunoassay), Specimen, Application (Infectious Diseases,
Oncology, Cardiology), End User (Hospitals) - Global Forecast to 2023",
The immunoassay market is expected to reach USD 27.15 Billion by 2023 from USD
20.19 Billion in 2018, at a CAGR of 6.1%.
The increasing incidence of chronic and infectious
diseases, technological advancements in immunoassay instruments and
introduction of novel automated systems, and growth in the biotechnology and
biopharmaceutical industries are some the major factors driving the growth of
this market.
By product and service, the
reagents and kits segment commanded the largest share of the market in 2017
On the basis product and service, this market is classified
into reagents and kits, analyzers, and software and services. In 2017, the
reagents and kits segment accounted for the largest share of the immunoassays
market. The large share of this segment can primarily be attributed to the
requirement of the repeat purchase of kits and reagents, coupled with the
increasing number of immunoassay tests being performed across the globe as a
result of the rising incidence of chronic and infectious diseases.
The chemiluminescence
immunoassays (CLIAs) segment led the immunoassays market in 2017
By platform, this market is classified into CLIAs,
radioimmunoassays (RIAs), colorimetric immunoassays (CIs), fluorescence
immunoassays (FIAs), and other platforms. The CLIAs segment accounted for the
largest share of the immunoassays market in 2017. The large share of this
segment can primarily be attributed to the low cost and high sensitivity of
CLIA-based tests.
By technology, the
enzyme-linked immunosorbent assays (ELISA) segment accounted for the largest
share of the market in 2017
On the basis of technology, the immunoassays market is
segmented into ELISA, rapid tests, western blotting, enzyme-linked immunospot
(ELISPOT), immuno-PCR, and other immunoassay technologies. The ELISA segment
accounted for the largest share of the immunoassays market in 2017. The large
share of this segment can primarily be attributed to the increasing use of
immunoassay tests in cancer, infectious diseases, and therapeutic drug level
monitoring.
North America held the
largest share of the market in 2017
Based on region, the immunoassay market is segmented into
North America, Europe, Asia Pacific, Latin America, and the Middle East &
Africa. North America dominated the market in 2017. The large share of this
regional segment is attributed to the increasing incidence of chronic diseases
and improved healthcare infrastructure.
Get Free Sample
Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=436
Key players in the immunoassays market include Roche
(Switzerland), Abbott Laboratories (US), Siemens (Germany), Danaher Corporation
(US), Sysmex Corporation (Japan), bioMérieux (France), Ortho Clinical
Diagnostics (US), DiaSorin (Italy), QIAGEN (Netherlands), Thermo Fisher
Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad
Laboratories (US), Agilent Technologies (US), PerkinElmer (US), Quidel
Corporation (US), Bio-Techne Corporation (US), and Mindray (China).
Contact:
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Comments
Post a Comment